What is it about?

Microbiological, clinical, and PK/PD features of aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam, and meropenem/vaborbactam

Featured Image

Read the Original

This page is a summary of: Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians, Pharmaceuticals, April 2022, MDPI AG,
DOI: 10.3390/ph15040463.
You can read the full text:

Read

Contributors

The following have contributed to this page